MannKind and Tolero Pharmaceuticals

[mango]

New Tolero Pharmaceuticals Trademark Filed on March 22, 2017


• Sumitomo Dainippon Pharma Co., Ltd. filed for international trademark protection for the mark "Tolero Pharmaceuticals" (same word mark as Tolero's original domestic trademark, which was registered on June 9, 2015).

• Sumitomo Dainippon Pharma Co., Ltd. officially acquired Tolero Pharmaceuticals on January 26, 2017.


—Tolero Pharmaceuticals new Trademark for International Registration Filed on March 22, 2017

New Tolero Pharmaceuticals International Trademark Registration


—Filing Receipt for Tolero Pharmaceuticals Trademark Application was filed on July 25, 2017

Filing Receipt for Trademark Application


• This is the first original Tolero Pharmaceuticals trademark which was registered on June 9, 2015. Notice that the Goods and Services are completely different compared to the new international registration trademark above.

Original Tolero Pharmaceuticals Trademark


• MannKind and Tolero Granted Joint Patent Published on July 25, 2017

Multiple kinase pathway inhibitors


• MannKind and Tolero International Joint Patent Application Published April 20, 2017

MULTIPLE KINASE PATHWAY INHIBITORS


• In case you didn't catch it—all of the MannKind and Tolero joint patents (including the ones I didn't include), including today's newly granted MannKind and Tolero joint patent, is for kinase pathway inhibitors. An international joint patent was filed on April 20, 2017 for Mulitple kinase pathway inhibitors as well, just one month after the new Tolero Pharmaceuticals international trademark was filed.


• Today, July 25, 2017, a newly granted joint patent was published plus the trademark filing receipt was filed today for the new Tolero trademark.

• Lastly, the first sentence in the new Tolero Pharmaceuticals international trademark Goods and Services is:

Pharmaceutical preparations comprising a kinase inhibitor;

the middle has

pharmaceutical preparations for the prevention and treatment of disorders and diseases of the metabolic system, namely, diabetes

and the last sentence is

pharmaceutical preparations for use in chemotherapy

• Original Tolero Pharmaceuticals Goods and Services

Bacteriological research; Bacteriological research and testing; Biochemical research and development; Biological research; Biomedical research services; Biotechnology research; Chemical analysis; Chemical engineering; Chemical laboratories; Chemical research; Chemical, biochemical, biological and bacteriological research and analysis; Chemist services; Conducting clinical trials for others; Conducting early evaluations in the field of new pharmaceuticals; Consultancy pertaining to pharmacology; Consulting services in the fields of biotechnology, pharmaceutical research and development, laboratory testing, diagnostics, and pharmacogenetics; Development of new technology for others in the field of pharmacology; Development of pharmaceutical preparations and medicines; Drug discovery services; Executing of chemical analyses; Genetic mapping for scientific purposes; Genetic testing for scientific research purposes; Genetic testing of laboratory animals for research purposes; Laboratory analysis in the field of pharmacology; Laboratory research services relating to pharmaceuticals; Medical and scientific research in the field of cancer treatment and diagnosis; Medical and scientific research in the field of pharmacology; Medical and scientific research information in the field of pharmacology; Medical and scientific research, namely, conducting clinical trials for others; Medical laboratory services; Medical research; Medical research services in the field of cancer; Performance of chemical analyses; Pharmaceutical drug development services; Pharmaceutical product evaluation; Pharmaceutical products development; Pharmaceutical research and development; Pharmaceutical research services; Providing laboratory research services in the field of gene expression, namely, cancer biology; Providing medical and scientific research information in the field of clinical trials; Providing medical and scientific research information in the field of pharmaceuticals and clinical trials; Providing medical and scientific research information in the fields of pharmaceuticals and genetics; Providing medical testing services and information in the field of cancer research and disease classification; Research and development in the pharmaceutical and biotechnology fields; Research and development of pharmaceuticals for the treatment of age-related diseases and cancer; Research in the field of chemistry; Research on the subject of pharmaceuticals; Research, development, engineering and testing services in the fields of immunopharmaceuticals and vaccines; Scientific investigations for medical purposes; Scientific laboratory services; Scientific research; Scientific research and development; Scientific research for medical purposes in the area of cancerous diseases; Scientific research in the field of genetics and genetic engineering; Testing, inspection or research of pharmaceuticals, cosmetics or foodstuff; Working on and evaluation of chemical analyses; Working on and evaluation of chemical syntheses

• New Tolero Pharmaceuticals Goods and Services

Pharmaceutical preparations comprising a kinase inhibitor; pharmaceutical preparations, namely, anti-inflammatories; pharmaceutical preparations for the prevention and treatment of disorders and diseases of the central nervous system, namely, diseases of the brain, movement, ocular motility and spinal cord diseases, encephalitis, epilepsy, Alzheimer's, cerebral palsy and Parkinson's disease and central nervous systems infections; pharmaceutical preparations for the prevention and treatment of disorders and diseases of the peripheral nervous system, namely, amyotrophic lateral sclerosis, numbness, lightheadedness, dysuria and dyshidrosis; pharmaceutical preparations for the prevention and treatment of disorders and diseases of the respiratory system; pharmaceutical preparations for the prevention and treatment of disorders and diseases of the urogenital system, namely, urological diseases, infertility, sexually transmitted diseases and inflammatory pelvic diseases; pharmaceutical preparations for the prevention and treatment of disorders and diseases of the cardiovascular system; pharmaceutical preparations for the prevention and treatment of disorders and diseases of the endocrine system, namely, growth and thyroid disorders; pharmaceutical preparations for the prevention and treatment of disorders and diseases of the metabolic system, namely, diabetes, hypoglycemia, gout, osteoarthritis, muscular dystrophy, anemia, bulimia nervosa, anorexia, obesity and hypothyroidism; pharmaceutical preparations for the prevention and treatment of disorders and diseases of the renal system; pharmaceutical preparations for the prevention and treatment of disorders and diseases of the gastroenterological system; pharmaceutical preparations for the prevention and treatment of disorders and diseases of the ophthalmologic system; pharmaceutical preparations for the prevention and treatment of disorders and diseases of the dermatologic system, namely, dermatitis, eczema, psoriasis, skin pigmentation diseases and sexually transmitted diseases; pharmaceutical preparations for the prevention and treatment of hematologic and oncologic disorders and diseases; pharmaceutical preparations for the prevention and treatment of psychiatric disorders and diseases, namely, anxiety disorders, mood disorders, schizophrenia, cognitive and bipolar disorders, epilepsy, Parkinson's disease, Alzheimer's disease, cerebral palsy, multiple sclerosis and seizures; pharmaceutical preparations for the prevention and treatment of allergic disorders and diseases and disorders and diseases of the immune system, namely, autoimmune diseases and immunologic deficiency syndromes; pharmaceutical preparations for the prevention and treatment of connective tissue and joints, namely, connective tissue diseases, bone diseases, spinal diseases, back pain, fractures and cartilage injuries; pharmaceutical preparations for the prevention and treatment of cancer; pharmaceutical preparations for use in chemotherapy

Mango here. Just reporting meaningful coincidences.

[n8]

Tolero and MannKind Sign Collaboration and License Agreement to Develop and Commercialize Novel BTK Inhibitors for Hematological Malignancies and Inflammatory Diseases So what happened to this agreement? And what happened with this "Under the terms of the agreement, Tolero will pay MannKind upfront and milestone payments linked to the development, approval and commercialization of products, for total potential upfront and milestone payments of approximately $130 million"?

[n8]

Would this help Mannkind?  "Under terms of the deal, Sumitomo will make an upfront payment of $200 million to Tolero on closing of the acquisition. The acquisition is expected to be finalized in February 2017. After that payment, Tolero shareholders will receive milestone payments of up to $430 million related to progress made on the compounds being developed by Tolero. Another $150 million in milestone payments will be made following the successful commercialization of these compounds, Sumitomo said in its announcement". Could this be a source of revenue and pay from the original 2012 agreement?

[mango]

Bruton's Tyrosine Kinase

BTK regulates

• innate immune activation

• inflammatory cytokine production

• immunoglobulin expression

• B-cell trafficking

• tissue homing

• adhesion to cellular substrates

• basophil/mast cell degranulation


The cellular and molecular mode of action of BTK explains its role in

• allergic, immune and inflammatory diseases


BTK activation plays a detrimental role in

• systemic lupus erythematosus

• rheumatoid arthritis

• synovitis


BTK regulates immune hypersensitivity responses such as

• allergic rhinitis

• dermatitis

• anaphylactic reaction

• passive cutaneous anaphylaxis


BTK mediates

• the amplification of inflammatory reactions driven through cytokine production and immune complex formation


BTK plays a critical role in

• neutrophil activation and recruitment after stimulation with chemokines or through selectins

• is necessary for efficient B-cell function, including cytokine secretion, integrin-mediated interactions, all of which activate immune responses and may become aberrantly activated in immune disorders, including in autoimmune and inflammatory disease such as rheumatoid arthritis, systemic lupus erythematosus, immune hypersensitivity, atopic asthma and other allergic disorders.


BTK participates in the transformation, proliferation, and drug resistance of hematologic malignancies

• B cell leukemias, for example, Acute Lymphocytic Leukemia (ALL), Chronic Lymphocytic Leukemia (CLL), Acute Myeloid Leukemia (AML), Chronic Myeloid Leukemia, (CML);

• B cell lymphomas, for example, Hodgkin's lymphoma (HL), and Non-Hodgkin's lymphoma (NHL) including the following types: Diffuse Large B-Cell Lymphoma (DLBCL), Follicular Lymphoma (FL), Mucosa-Associated Lymphatic Tissue (MALT) Lymphoma Small Cell Lymphocytic Lymphoma-Chronic Lymphocytic Leukemia (SLL/CLL), Mantle Cell Lymphoma (MCL), Large B-Cell Lymphoma, Lymphoplasmacytic Lymphoma (aka Waldenstrom Macroglobulinemia), Marginal Zone Lymphoma (MZL), Hairy cell leukemia (HCL) and Burkitt Lymphoma-Burkitt Leukemia (BL);

• Myelomas, including multiple myeloma (MM) and plasmacytoma; and

• Mast cell malignancies, including mastocytoma and mast cell leukemia 

[thall]

Jul 25, 2017 15:42:55 GMT -5 n8 said:

Would this help Mannkind?  "Under terms of the deal, Sumitomo will make an upfront payment of $200 million to Tolero on closing of the acquisition. The acquisition is expected to be finalized in February 2017. After that payment, Tolero shareholders will receive milestone payments of up to $430 million related to progress made on the compounds being developed by Tolero. Another $150 million in milestone payments will be made following the successful commercialization of these compounds, Sumitomo said in its announcement". Could this be a source of revenue and pay from the original 2012 agreement?

I think if you check, you'll find that the figures you quote are in yen, not dollars. 200 million yen is only 1.8 million dollars.

[majorwood]

Nope that's US Dollars smarty pants.